- HHS 2022 Strategic Plan Comments HHS 2022 Strategic Plan Comments Comments in response HHS’ FY 2022 – 2026 draft Strategic Plan Read more about this post
- Coalition Letter to House Energy & Commerce Committee Leadership Regarding Action on Recommendations Made by the HHS Pain Management Best Practices Inter-Agency Task Force – 10-15-20 Read more about this post
- PAPR Coalition CDC RFC Comments Comments in response to the Request for Comment entitled “Management of Acute and Chronic Pain” (Docket No. CDC-2020-0029) issued by the Centers for Disease Control and Prevention (CDC) PAPR Coalition CDC RFC Comments – CDC-2020-0029 – 6-16-20 Read more about this post
- Comments Submitted to the Agency for Healthcare Research and Quality (AHRQ) in Response to Their RFI Related to the “Opioid Management in Older Adults” Project Download PDF Read more about this post
- PAPR Coalition CMS RFI Comments PAPR Coalition Comments in Response to a CMS RFI for Development of a CMS Action Plan to Prevent Opioid Addiction and Enhance Access to Medication-Assisted Treatment Read more about this post
- Comments Submitted to HHS’ Pain Management Best Practices Inter-Agency Task Force in Response to Their Draft Report on Pain Management Best Practices PAPR Coalition Pain Management BPITF Draft Report Comments April 2019 Read more about this post
- Comments Submitted to HHS’ Pain Management Best Practices Inter-Agency Task Force in Response to Their Inaugural Meeting June 15, 2018 Alicia Richmond Scott Pain Management Best Practices Inter-Agency Task Force U.S. Department of Health and Human Services 200 Independence Avenue, SW Washington, DC 20201 RE: Docket No. HHS-OS-2018-0009-0001 Dear Ms. Scott: The undersigned members of the Protecting Access to Pain Relief (PAPR) Coalition wish to submit written comments in response to “Meeting of the Pain Management Best Practices Inter-Agency Task ... Read more about this post
- Comments Submitted to FDA’s Opioid Policy Steering Committee Regarding the PAPR Coalition’s Actions to Address the Opioid Epidemic December 27, 2017 Kathleen Davies Office of Medical Products and Tobacco U.S. Food and Drug Administration 10903 New Hampshire Avenue Building 1, Room 2310 Silver Spring, MD 20993 Docket No. FDA-2017-N-5608 Dear Ms. Davies: As undersigned members of the Protecting Access to Pain Relief (PAPR) Coalition, we wish to submit written comments in response to “Opioid Policy Steering Committee; Establishment of a Public Docket; ... Read more about this post
- Comments Submitted to NIH’s Interagency Pain Research Coordinating Committee October 16, 2017 Linda L. Porter, PhD Pain Policy Advisor, Office of Pain Policy Office of the Director National Institute of Neurological Disorders and Stroke 31 Center Drive, Room 8A31 Bethesda, MD 20892 Dear Dr. Porter: As undersigned members of the Protecting Access to Pain Relief (PAPR) Coalition, we wish to submit written comments in response to a meeting of the Interagency Pain ... Read more about this post
- Comments Submitted to the FDA’s Office of Patient Affairs Regarding Its Efforts to Enhance Its Patient Engagement Efforts Agency-Wide May 5, 2017 Sharnell Ligon Division of Dockets Management (HFA–305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 RE: Public Comments on Docket No. FDA–2017–N–0455 for “Enhancing Patient Engagement Efforts Across FDA; Establishment of a Public Docket; Request for Comments.” Dear Ms. Ligon, The following are the comments of the Protecting Access to Pain Relief (PAPR) Coalition on ... Read more about this post
